

# 1. Mitteilungsblatt

## Nr. 1

Mitteilungsblatt der Medizinischen Universität Wien  
Studienjahr 2024/2025  
1. Stück; Nr. 1

Bevollmächtigungen

1. Bevollmächtigungen gem. § 27 Abs. 2 UG

## 1. Bevollmächtigungen gem. § 27 Abs. 2 UG

Gemäß § 27 Abs. 2 UG werden folgende Bevollmächtigungen erteilt:

<b>Auftragsnummer</b>	<b>Projekttitle</b>	<b>Organisationseinheit</b>	<b>Projektleiter(in)</b>
FA731A0106	Characterization myeloid cells in CRC including peritoneal metastasis and development of autologous organotypic assays	Allgemeinchirurgie_731	Oehler Rudolf
FA731B2201	Efficacy of NHS-PEG coated collagen patch (Hemopatch) for prevention of bile leaks after liver resection - a power analysis.	Allgemeinchirurgie_731	Schwarz Christoph
FA731B2305	A Phase III, randomized, open-label, multicenter study, evaluating the efficacy and safety of adjuvant Giredestrant compared with physician's choice of adjuvant endocrine monotherapy in patients with estrogen receptor positive, Her2-negative early breast cancer	Allgemeinchirurgie_731	Exner Ruth
FA731B2405	A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degradar) Versus Standard Endocrine Therapy (Aromastase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/Her2- Early Breast Cancer and an Intermediate-High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have no Evidence of Disease	Allgemeinchirurgie_731	Exner Ruth
FA731B2601	Präklinische Evaluation der Anwendbarkeit von Tumorstimmungsimpfungen nach dem Rinnale Prinzip bei weiteren Tumorentitäten	Allgemeinchirurgie_731	Silberhumer Gerd
FA731E0210	Combination cell therapy for immunomodulation in kidney transplantation	Allgemeinchirurgie_731	Wekerle Thomas

FA731E0611	A prospective, randomized, single blind, multicentre phase III study on organ preservation with Custodiol-N solution compared with Custodiol solution in organ transplantation (kidney, liver and pancreas)	Allgemeinchirurgie_731	Berlakovich Gabriela
FA738A0812	Ärzte Ausbildung 4.0	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Kimberger Oliver
FA738A1303	Klinischen Prüfung der pharmakologische Sicherheit und Wirksamkeit des Prüfpräparates AP301 powder for reconstitution for solution for inhalation in Patienten mit pulmonalem Permeabilitätsödem bei Patienten mit mäßigem bis schwerem akutem Atemnotsyndrom (ARDS)	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Schaller Stefan
FA738A2101	Feasibility of a neuromuscular electrostimulation device for mechanical thromboprophylaxis in ICU patients	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Wiegele Marion
FA738A3001	Relevance of reversible causes during out-of-hospital cardiac arrest	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Lintschinger Josef Michael
FA738C1101	Amino acid supplementation during continuous renal replacement therapy in critically ill patients	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Fischer Arabella
UE73806005	Osteoarthritis and Pain	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Weigl Lukas
FA611A0201	Femoral stability after Intramedullary Nail Removal	Anatomie und Zellbiologie_310	Hirtler Lena
FA611A0401	3D-Druck von extrazellulären Vesikeln aus mesenchymalen Stammzellen des Hoffa Fettkörper für die Knorpelregeneration	Anatomie und Zellbiologie_310	Reissig Lukas
FA611A0401	3D-Druck von extrazellulären Vesikeln aus mesenchymalen Stammzellen des Hoffa Fettkörper für die Knorpelregeneration	Anatomie und Zellbiologie_310	Reissig Lukas

FA611A0501	Viral Infectiology Research with Advanced Laboratory models	Anatomie und Zellbiologie_310	Geyer Stefan
FA613A0502	SFB 80 RNAdeco: decorating RNA for a purpose/ Teilprojekt 07: Molekulare Konsequenzen der Adenosine Desaminierung	Anatomie und Zellbiologie_310	Jantsch Franz-Michael
FA613A0503	SFB 80 RNAdeco: decorating RNA for a purpose/ Koordinationsprojekt 01	Anatomie und Zellbiologie_310	Jantsch Franz-Michael
FA613A0701	SFB 80 RNAdeco: decorating RNA for a purpose/ Teilprojekt 14: Struktur-Funktionsuntersuchungen an Spezifischen tsRNAs	Anatomie und Zellbiologie_310	Schäfer Matthias
FA613A0801	SFB 80 RNAdeco: decorating RNA for a purpose/ Teilprojekt 15: tRNA-Modifikationslandschaften und ihr Einfluss auf die Translation	Anatomie und Zellbiologie_310	Vilardo Elisa
FA613A0901	The epigenetics of the spermatozoa of HIV-I infected men	Anatomie und Zellbiologie_310	Wossidlo Mark
FW613A0201	The function of MORC4 in human trophoblast identity	Anatomie und Zellbiologie_310	Latos Paulina
FW613A0202	Deciphering BMP signaling in human lateral plate mesoderm	Anatomie und Zellbiologie_310	Latos Paulina
FW613A0301	Single-cell proteomics to resolve first cell fate decisions	Anatomie und Zellbiologie_310	Arand Julia
FW613A0101	Preserving the Immunological Memory of Previous Generations	Anatomie und Zellbiologie_310	Schäfer Matthias
FA746A0802	VEREINBARUNG FÜR ALLGEMEINE UNTERSTÜTZUNG IN FORSCHUNG UND LEHRE	Augenheilkunde und Optometrie_746	Abela-Formanek Claudette
FA746A1639	A multicenter, open-label extension study to evaluate the long-term safety and tolerability of Faricimab in patients with neovascular age-related macular degeneration	Augenheilkunde und Optometrie_746	Sacu Gülhan Stefan
FA746A1654	A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)	Augenheilkunde und Optometrie_746	Sacu Gülhan Stefan
FA746A2007	General Research Funding André	Augenheilkunde und Optometrie_746	Stifter Eva

FA746A2610	An Open-label Study to Investigate the Safety, Tolerability, and Exposure of Single Ascending Doses of the Antisense Oligonucleotide STK-002 in Patients with Autosomal Dominant Optic Atrophy	Augenheilkunde und Optometrie_746	Pemp Berthold
FA746A2612	A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset Epilepsy	Augenheilkunde und Optometrie_746	Pemp Berthold
FA746A3304	A Phase 2b Pivotal Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Non-infectious, Intermediate-, Posterior- or Pan-uveitis	Augenheilkunde und Optometrie_746	Funk Marion
FA746A4002	A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD	Augenheilkunde und Optometrie_746	Aschauer Julia
FA662A1002	REZOT	Biomedizinische Forschung und Translationale Chirurgie_308	Hohensinner Philipp
FA662A1003	REZOT	Biomedizinische Forschung und Translationale Chirurgie_308	Hohensinner Philipp
FA662A0503	"In vivo study of a compliant graft material for treatment for the treatment of aortic disease"	Biomedizinische Forschung_308	Podesser Bruno Karl
FA727A0606	A Phase 2, Single-Arm, Multi-Cohort, Multi-Center Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects with Aggressive B-Cell Non-Hodgkin Lymphoma	Blutgruppenserologie und Transfusionsmedizin_727	Worel Nina

FA727A0609	Phase I, open Label, multicenter, dose escalation 2055/20 and DLBCL	Blutgruppenserologie und Transfusionsmedizin_727	Worel Nina
FA727A0616	A pivotal Phase II randomised, multicentre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with relapsed/refractory diffuse large B-Cell Lymphoma (R-R DLBCL)	Blutgruppenserologie und Transfusionsmedizin_727	Worel Nina
CD10272203	Christian Doppler Labor für Chronisch-entzündliche Hautkrankheiten	Dermatologie_722	Stary Georg
FA722A0505	A randomized, subject and investigator blinded, placebo-controlled and multi-center platform study, to assess efficacy and safety of different investigational drugs in patients with moderate to severe hidradenitis suppurativa	Dermatologie_722	Jonak Constanze
FA722A1402	Methylation profiling: In search for predictive biomarkers for response to checkpoint inhibitors in Non-Melanoma Skin Cancer - EADO research collaboration	Dermatologie_722	Ressler Julia Maria
FA722A2001	Skin microbial metabolites and antimicrobial peptides at the interface of skin-gut inflammation	Dermatologie_722	Palomo Irigoyen Marta
FA722A2101	A Multicenter, Randomized, Parallel-group, Double-blind, Two-arm, Phase III Study to Evaluate the Safety and Efficacy of Anifrolumab Compared with Placebo in Male and Female Participants 18 to 70 Years of Age Inclusive with Systemic Sclerosis (DAISY)	Dermatologie_722	Riedl Elisabeth
FA722A2201	Deciphering the impact of cancer-associated fibroblasts on immune cell activation and infiltration in skin tumors.	Dermatologie_722	Aschenbrenner Bertram

FA722B1118	Adjuvante Immuntherapie mit monoklonalem Anti-PD-1-Antikörper Pembrolizumab (MK-3475) im Vergleich zu Placebo nach vollständiger Resektion eines Hochrisiko-Melanoms im Stadium III: Eine randomisierte, doppelblinde Phase-3-Studie der EORTC-Melanomgruppe, EORTC-Prüfplan 1325-MG -906.	Dermatologie_722	Höller Christoph
FA722B1128	CA224-047: A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma.	Dermatologie_722	Höller Christoph
FA722B1131	Neo-BCC trial: Neoadjuvante Therapie beim lokal fortgeschrittenen, schwer rezidierbaren Basalzellkarzinom (BCC) mit Talimogene Laherparepvec (T-VEC)	Dermatologie_722	Höller Christoph
FA722B2311	Sweet solution for scar-less healing	Dermatologie_722	Mildner Michael
FA722C0728	PollenAI Detect	Dermatologie_722	Epstein Michelle
FA722C0729	In vitro and in vivo models developmentfor the predicton of sensitzaton to food.	Dermatologie_722	Epstein Michelle
FA722C1210	Durchführung der HAE Survey Patientenpräferenz	Dermatologie_722	Kinaciyan Tamar
FA722C1409	A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination with Topical Corticosteroids in Adolescent und Adult Subjects with Moderate to Severe Atopic Dermatitis.	Dermatologie_722	Bangert Christine
FW722A0401	Subtype-resolved characterisation of human alopecia areata	Dermatologie_722	Griss Johannes Maximilian
FA751B0504	Labortechniken	Frauenheilkunde_751	Kiss Herbert
FA751B0602	The Effectiveness of Real Time Continuous Glucose Monitoring to Improve Glycemic Control and Pregnancy Outcomes in Patients with Gestational Diabetes Mellitus	Frauenheilkunde_751	Göbl Christian

FA751C0133	A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients	Frauenheilkunde_751	Polterauer Stephan
FA751C0519	A randomized, parallel-group treatment, Phase 2, double-blind pilot study to investigate the efficacy and safety of elinzanetant compared with placebo for treatment of sleep disturbances associated with menopause	Frauenheilkunde_751	Wenzl René
FA751C1608	A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants with Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy	Frauenheilkunde_751	Polterauer Stephan
FA751C1609	The Role of ARID1A Expression as a Predictive and Prognostic Biomarker in Endometrial Cancer of No Specific Molecular Subtype (NSMP): A Translational Pilot Study	Frauenheilkunde_751	Polterauer Stephan
FA751C2103	A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degradar) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease	Frauenheilkunde_751	Seifert Michael



FA751D1206	A randomized, parallel-group treatment, Phase 2, double-blind pilot study to investigate the efficacy and safety of elinzanetant compared with placebo for treatment of sleep disturbances associated with menopause	Frauenheilkunde_751	Ott Johannes
FA751D1402	Wirksamkeit von Vitex agnus-castus BNO 1095 (20 mg) bei Frauen mit primärer Dysmenorrhoe	Frauenheilkunde_751	Hager Marlene
FW751B0101	Maternal immune responses induced by human placentation	Frauenheilkunde_751	Pollheimer Jürgen
FA744A0202	Effects of locally applied glucocorticoids and selective glucocorticoid receptor agonists on the inner ear in an animal model	Hals-, Nasen- und Ohrenkrankheiten_74 4	Arnoldner Christoph
FA744A0202	Effects of locally applied glucocorticoids and selective glucocorticoid receptor agonists on the inner ear in an animal model	Hals-, Nasen- und Ohrenkrankheiten_74 4	Arnoldner Christoph
FA744A0205	Phase II, Multi-Center, Randomized, Blinded Study Evaluating the Efficacy, Safety and Tolerability of a Single Intratympanic Dose of AC102 Compared to Oral Steroids for the Treatment of ISSHL	Hals-, Nasen- und Ohrenkrankheiten_74 4	Arnoldner Christoph
FA744B0906	Effect of Dupilumab on nasal epithelial barrier function in patients with Chronic Rhinosinusitis with nasal polyps (CRSwNP) – an exploratory pilot study	Hals-, Nasen- und Ohrenkrankheiten_74 4	Schneider Sven-Thorben
FA744B1202	Moving towards PREcision Medicine In United airways disease: Unravel-ling inflamMatory patterns in asthmatic patients with or without nasal polyps (PREMIUM) – an exploratory pilot study	Hals-, Nasen- und Ohrenkrankheiten_74 4	Eckl-Dorna Julia
FA731C1412	Forschungsförderung GIGAX Stiftung	Herzchirurgie_732	Zimpfer Daniel
FA731C2203	Forschungsprojekt Xenios: "Efficassy i-cor-synchronised cardiac assist"	Herzchirurgie_732	Zimpfer Daniel

FA732A0104	The German Multicenter Pediatric Cardiac Surgery Group: Congenital Heart Adhesion Prophylaxis	Herzchirurgie_732	Zimpfer Daniel
FA732A0308	Clinical Safety and Efficacy of the V-Dyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation (VISTA)	Herzchirurgie_732	Andreas Martin
FA732A0402	Noninvasive Cardiovascular Diagnosis of Patients With Fully Magnetically Levitated Blood Pumps	Herzchirurgie_732	Schlöglhofer Thomas
FA732A0405	Non-invasive monitoring of fully magnetically levitated left ventricular assist devices – HeartMate 3 Snoopy	Herzchirurgie_732	Schlöglhofer Thomas
FA732A0408	Comparison of Silverlon and Usual Care for Preventing LVAD Driveline Infections: A Clinical Study	Herzchirurgie_732	Schlöglhofer Thomas
FA732A0409	In Vitro Analysis of the CathGrip Securement System: Preventing ECMO Cannula Dislodgement and Infections	Herzchirurgie_732	Schlöglhofer Thomas
FA732A0410	HeartMate 3 Snoopy - Cardiopulmonary Exercise Testing: Optimizing outcomes by identifying patients that may benefit from speed changes	Herzchirurgie_732	Schlöglhofer Thomas
FA732A0508	CorWave Assessment of hemolysis under realistic operating conditions	Herzchirurgie_732	Granegger Marcus
FA732A0509	PReduction Hemolysis test	Herzchirurgie_732	Granegger Marcus
FA732A0802	The Canadian CABG or PCI in Patients with Ischemic Cardiomyopathy (Stich 3.0)	Herzchirurgie_732	Sandner Sigrid
FA732A0901	Impella in der Herzchirurgie (ImCarS) - Studienregister und Studien Plattform für mechanische Herzunterstützung und Nachlastreduktion - eine multizentrische Studie	Herzchirurgie_732	Riebandt Julia
FA732A0902	Prospective Multi-Center Single-Arm Study for Evaluating the Corheart 6 Ventricular Assist System	Herzchirurgie_732	Riebandt Julia
FA732A1001	Fellowship Aorten Chirurgie	Herzchirurgie_732	Ehrlich Marek

FA732A1101	ADEPT-Antegrade Deployment Tool	Herzchirurgie_732	Stelzmüller Marie - Elisabeth
FA732A1201	Multicenter Trial. Safety and Efficacy of Low-Level Transcutaneous Electrical Auricular Nerve Stimulation to Suppress Atrial Fibrillation and Reduce Systemic Inflammation Following Cardiac Surgery	Herzchirurgie_732	Kocher Alfred
FA684A0103	Identification of readouts for the evaluation of treatment strategies in RCDP	Hirnforschung_360	Berger Johannes
FW627A0101	Bifurcation analysis on diverse cell types and systems	Hirnforschung_360	Adameyko Igor
FW629A0101	Documents for A14 neurons in mediating neuromedin-S effect on feeding	Hirnforschung_360	Romanov Roman
FA711A0165	Randomisierte Studie zur Wirksamkeit einer Cetuximab-Reexposition bei Patienten mit metastasiertem kolorektalem Karzinom (RAS Wildtyp), welche auf eine Erstlinien-Behandlung mit FOLFIRI plus Cetuximab ein Ansprechen zeigten	Innere Medizin I_711	Preusser Matthias
FA711A0601	Assessment of drug-mediated mast cell activation	Innere Medizin I_711	Starkl Philipp
FA711A0604	Exploration of genetic mast cell recovery programs	Innere Medizin I_711	Starkl Philipp
FA711B0475	APHINITY - A Randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer	Innere Medizin I_711	Preusser Matthias
FA711B0556	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) plus LY2835219, a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Locoregionally Recurrent or Metastatic Breast Cancer with No Prior Systemic Therapy in this Disease Setting	Innere Medizin I_711	Preusser Matthias

FA711B0566	A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in BRCA mutated high risk HER2-negative breast cancer patients who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy (OLYMPIA)	Innere Medizin I_711	Preusser Matthias
FA711B0712	Randomisierte Phase II, 2-Arm Studie bei für Transplantation ungeeignete Patienten mit neu diagnostizierten multiplen Myelom (NDMM) zum Vergleich von Carfilzomib + Thalidomid + Dexamethason (KTD) Induktionstherapie mit Carfilzomib + Lenalidomid + Dexamethason (KRD) Induktionstherapie in Bezug auf Ansprechraten und Untersuchung einer Monotherapie mit Carfilzomib (K) als Erhaltungstherapie (AGMT_M	Innere Medizin I_711	Valent Peter
FA711B0810	A prospective, open, randomized, phase II study of carboplatin/olaparib in the pre-operative treatment of patients with triple-negative primary breast cancer which exhibit the features of positive homologous recombination deficiency (HRD) status	Innere Medizin I_711	Preusser Matthias
FA711B0936	a non-interventional study to assess the safety and efficacy of first line therapy with Vectibix® in combination with FOLFIRI or FOLFOX and to validate a prognostic score in adult patients with RAS wild-type metastatic colorectal cancer in a real world setting	Innere Medizin I_711	Preusser Matthias
FA711B0948	a phase-II study of Trastuzumab-Deruxtecan in HER2-positive breast cancer, patients with newly diagnosed or progressing brain metastases	Innere Medizin I_711	Preusser Matthias

FA711B0953	a phase-II, randomized, active-controlled, multi-center study comparing the efficacy and safety of targeted therapy or cancer immunotherapy guided by genomic profiling versus platinum-based chemotherapy in patients with cancer of unknown primary site who have received three cycles of platinum doublet chemotherapy	Innere Medizin I_711	Preusser Matthias
FA711B0955	a phase-3, randomized, double-blind study of Pamrevlumab or placebo in combination with Gemcitabine plus Nab-paclitaxel as neoadjuvant treatment in patients with locally advanced unresectable pancreatic cancer	Innere Medizin I_711	Preusser Matthias
FA711B0966	a randomized, double-blind placebo-controlled, phase-3 study of Debio 1143 in combination with platinum-based chemotherapy and standard fractionation intensity-modulated radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck, suitable for definitive chemotherapy (TrilynX)	Innere Medizin I_711	Preusser Matthias
FA711B0980	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 2a or R/R Marginal Zone Lymphoma (INCMOR0208-301_inMIND)	Innere Medizin I_711	Preusser Matthias
FA711B0988	A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy	Innere Medizin I_711	Preusser Matthias

FA711B1025	Lomustine with and without reirradiation for first progression of glioblastoma: a randomized phase III study	Innere Medizin I_711	Preusser Matthias
FA711B1026	Tucatinib bei Patienten mit lokal fortgeschrittenem oder metastasiertem HER2+ Mammakarzinom, die zuvor mit mindestens zwei anti-HER2-basierten Therapieregimen behandelt wurden: eine multizentrische, internationale, prospektive, nicht-interventionelle Studie in Deutschland und Österreich	Innere Medizin I_711	Preusser Matthias
FA711B1027	A Prospective non-interventional study (NIS) of trastuzumab deRuxtecán (T-DXd) for adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior Trastuzumab-based regimen, accompanied by a disease registry of patients treated with conventional therapies in a real-world setting in Europe. (PROSPERITY)	Innere Medizin I_711	Preusser Matthias
FA711B1028	SAGA - A Phase Ib/II single-arm, multicenter study of sacituzumab-govitecan, a TROP-2 targeting antibody linked with SN38, for patients with metastatic esophagogastric adenocarcinoma	Innere Medizin I_711	Preusser Matthias
FA711B1029	A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2-Negative (HER2-) (HER2 IHC0 or HER2-low [IHC1+, IHC2+/ISH-]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy	Innere Medizin I_711	Preusser Matthias
FA711B1030	A phase II study assessing safety and efficacy of REPotrectinib in ROS1-positive non-small cell lung cancer patients with active brain metastasis (REPOSE)	Innere Medizin I_711	Preusser Matthias

FA711B1031	A randomized, phase 3, open-label study to evaluate SGN-B6A compared with docetaxel in adult subjects with previously treated non-small cell lung cancer	Innere Medizin I_711	Preusser Matthias
FA711B1032	A randomized, double-blind, placebo-controlled, 2-arm-Phase III study to assess efficacy and safety of xevinapant and radiotherapy compared to placebo and radiotherapy for demonstrating improvement of disease-free survival in participants with resected squamous cell carcinoma of the head and neck, who are at high-risk for relapse and are ineligible for high-dose cisplatin	Innere Medizin I_711	Preusser Matthias
FA711B1033	Phase II Study of Trastuzumab-Deruxtecan (T-DXd; DS-8201a) in HER2-Low reast Cancer Patients Presenting with Newly diagnosed or Progressing Brain Metastases (The TUXEDO-4 Study)	Innere Medizin I_711	Preusser Matthias
FA711B1034	Phase 3, interventional multicentre, open-label, randomized study comparing rituximab plus zanubrutinib to rituximab monotherapy in previously untreated, symptomatic splenic marginal zone lymphoma (RITZ)	Innere Medizin I_711	Preusser Matthias
FA711C0377	Eine prospektive, nicht-interventionelle Studie zur Beobachtung der Wirksamkeit von AFSTYLA, ein B-Domänverkürztes rekombinantes Faktor VIII Präparat mit einer einkettigen Proteinstruktur (rVIII Single-Chain) bei Patienten mit Hämophilie A	Innere Medizin I_711	Pabinger Ingrid
FA711C0632	JHTB-Studie - A Phase 2 Study of LY2784544 in Patients with Myeloproliferative Neoplasms	Innere Medizin I_711	Valent Peter
FA711C0661	Registry and Biobank for the collection of clinical data and biomaterial from adult ALL patients (AGMTALLReg)	Innere Medizin I_711	Valent Peter
FA711C0949	Doc@Home - telemedizinische Unterstützung von TumorpatientInnen.	Innere Medizin I_711	Valent Peter

FA711C0950	EMN Biobanking Project	Innere Medizin I_711	Valent Peter
FA711C0951	Phase 3 Study of Teclistamab in Combination with Lenalidomide versus Lenalidomide Alone in Participants with Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4, EMN30) EudraCT Number: 2021-002531-27	Innere Medizin I_711	Valent Peter
FA711C0952	CA058-1019: A Phase 3 Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants with Relapsed or Refractory Multiple Myeloma (RRMM)	Innere Medizin I_711	Valent Peter
FA711C0953	Observation of AML CR1 maintenance therapy with particular emphasis on handling the self-injection of histamine dihydrochloride and Interleukin-2	Innere Medizin I_711	Valent Peter
FA711C0956	A non-interventional study of selinexor (Nexpvio®) in combination with bortezomib and dexamethasone (SVd) in patients with relapsed or refractory multiple myeloma (R/RMM)	Innere Medizin I_711	Valent Peter
FA711C1082	A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia	Innere Medizin I_711	Jäger Ulrich
FA711C1301	AERN - Abscopal Effect of Radiotherapy and Nivolumab in anti-PD1 Pretreated Relapsed or Refractory classical Hodgkin Lymphoma - An international multicenter Phase II trial	Innere Medizin I_711	Valent Peter
FA711C1304	Eine multizentrische, offene Phase-III-Langzeitstudie zur Beurteilung der Sicherheit und Wirksamkeit von intravenös verabreichtem Efgartigimod (ARGX-113) 10 mg/kg bei erwachsenen Patienten mit primärer Immunthrombozytopenie	Innere Medizin I_711	Valent Peter



FA711C1309	A Phase 2, Open-Label, Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Proof-of-Concept of Intravenous ANX005 in Subjects with Warm Autoimmune Hemolytic Anemia	Innere Medizin I_711	Jäger Ulrich
FA711C1421	CSL222_4001: A Post-authorization Long-term Follow-up Study to Characterize the Safety and Effectiveness of HEMGENIX (Etranacogene Dezaparvovec) in Patients with Hemophilia B	Innere Medizin I_711	Ay Cihan
FA711D0305	CAPNETZ - Epidemiologische Studie und Aufbau einer Biobank zur ambulant erworbenen Pneumonie	Innere Medizin I_711	Burgmann Heinz
FA711D0315	Observational Study on the Clinical Use of EVUSHELD (AZD7442) in Austria	Innere Medizin I_711	Burgmann Heinz
FA711D0318	Retrospective data collection on RSV and associated burden in adult inpatients in Austria	Innere Medizin I_711	Burgmann Heinz
FA714B0397	IMPAHCT-FUL: A Long-Term Extension, Multi-Center Safety Study of AV-101 in Subjects With Pulmonary Arterial Hypertension (PAH) Who Have Completed Study AV-101-002" under protocol AV-101-003 including all amendments thereto, which in each case shall be automatically incorporated therein (the "Protocol") for the following Study Drug: AV-101 (the "Study Drug")	Innere Medizin II_714	Lang Irene
FA714B0398	A Phase 3, Randomized Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in newly Diagnosed Intermediate- and High risk patients	Innere Medizin II_714	Lang Irene
FA714B0538	Animal study protocol Hbtological and pharmacoknotlc assessment of use of new drug-coated balloon in rabbit iliac arteries	Innere Medizin II_714	Pavone-Gyöngyösi Mariann

FA714B1715	Product Surveillance Registry - Cardiac Rhythm and Heart Failure	Innere Medizin II_714	Gwechenberger Marianne
FA714B3110	A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIb AL Amyloidosis	Innere Medizin II_714	Kastner Johannes
FA714B3111	A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIa AL Amyloidosis	Innere Medizin II_714	Kastner Johannes
FA714B4213	Präprozedurale Beurteilung der koronaren Herzkrankheit bei Patienten, die sich einer Transkatheter-Aortenklappenimplantation (TAVI) unterziehen; Vergleich von Pre-TAVI CTA v. Pre-TAVI ICA - Das EASE-IT CT Register	Innere Medizin II_714	Hengstenberg Christian
FA714B4214	A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the progression of calcific aortic valve stenosis [Lp(a)FRONTIERS CAVS]“ - interner Studiencode CTQJ230A12203	Innere Medizin II_714	Hengstenberg Christian
FA714B4303	A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with TQJ230 on major cardiovascular events in patients with established cardiovascular disease	Innere Medizin II_714	Speidl Walter

FA714B4306	A phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a) who have Established Atherosclerotic Cardiovascular Disease of Are at Risk for a Fort Cardiovascular Event - ACCLAIM-Lp(a)	Innere Medizin II_714	Speidl Walter
FA714B4704	Eine randomisierte, doppelblinde, placebokontrollierte, klinische Parallelgruppenprüfung zur Beurteilung der Wirksamkeit und Sicherheit von Baxdrostat bei Prüfungsteilnehmer:innen mit unkontrollierter Hypertonie mit zwei oder mehr Medikamenten, einschließlich Prüfungsteilnehmer:innen mit resistenter Hypertonie	Innere Medizin II_714	Badr Eslam Roza
FA714B4705	A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Amyloid Deleter ALXN2220 in Adult Participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)	Innere Medizin II_714	Badr Eslam Roza
FA714B4913	A Randomized Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination with Irinotecan versus Investigator`s Choice (Topotecan or Irinotecan) in Relapsed Small Cell Lung Cancer (SCLC) Patients (LAGOON Trial) ("Trial")	Innere Medizin II_714	Kastl Stefan
FA714B4914	ABX464-105	Innere Medizin II_714	Kastl Stefan
FA714B4915	A randomized, double-blind, multicenter phase III study to evaluate to long-term efficacy and safety of ABX464-25 mg or 50 mg once daily as a maintenance therapy in subjects with moderately to severely active ulcerative colitis	Innere Medizin II_714	Kastl Stefan
FA714B5801	"Novel biomarkers"	Innere Medizin II_714	Mayr Manuel

FA714C0313	Effects of Semaglutide on functional capacity in patients with type 2 diabetes and peripheral arterial disease; Protocol ID: NN9535-4533	Innere Medizin II_714	Schernthaler Gerit
FA714C0710	Prospective, multicentre single-arm Post-Market Clinical Follow-up (PMCF) study to evaluate safety and performance of the BeYond Venous Self-Expanding Stent	Innere Medizin II_714	Schlager Oliver
FA714D0509	Effect of Dupilumab on mucus plugs and inflammatory patterns in severe asthmatic patients	Innere Medizin II_714	Idzko Marco
FA714D0510	Asthmakontrolle bei Patienten mit schwerem Asthma, die mit Tezepelumab behandelt werden: eine prospektive, evidenzbasierte Beobachtungsstudie anhand eines Fallbeispiels (ASCENT)	Innere Medizin II_714	Idzko Marco
UE71406018	Forschungszuwendungen	Innere Medizin II_714	Hemetsberger Rayyan
FA716B0625	Eine randomisierte, doppelblinde, ereignisgesteuerte Parallelgruppen-Studie der Phase III zur kardiovaskulären Sicherheit von subkutan verabreichtem BI 456906 im Vergleich zu Placebo bei Teilnehmern mit Übergewicht oder Adipositas mit nachgewiesener kardiovaskulärer Erkrankung (KVE) oder chronischer Nierenerkrankung und/oder mindestens zwei gewichtsbedingten Komplikationen oder Risikofaktoren für KVE.	Innere Medizin III_716	Kautzky-Willer Alexandra

FA716B0626	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants with Body Mass Index $\geq 27$ kg/m <sup>2</sup> and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease	Innere Medizin III_716	Kautzky-Willer Alexandra
FA716B0627	A Phase IIb, Multicentre, Randomised, Double-Blind, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Balcinrenone in Combination with Dapagliflozin Compared with Dapagliflozin in Patients with Chronic Kidney Disease and Albuminuria (MIRO-CKD)	Innere Medizin III_716	Kautzky-Willer Alexandra
FA716B1310	Evaluation of long-term complications after bariatric surgery - A questionnaire-based long-term follow-up pilot study	Innere Medizin III_716	Krebs Michael
FA716B1403	PARADIGHM (Physicians Advancing Disease Knowledge in Hypoparathyroidism- Erweiterung des Wissenstandes von Ärzten bezüglich Hypoparathyreoidismus): Eine Registrierstudie für Studienteilnehmer mit chronischem Hypoparathyreoidismus	Innere Medizin III_716	Vila Greisa
FA716C0915	Safety, Tolerability and Efficacy of Monoclonal CD38 Antibody Felzartamab in Late Antibody-Mediated Renal Allograft Rejection – A Phase 2 Pilot Trial	Innere Medizin III_716	Böhmig Georg
FA716C1023	A Phase 3 open-label, controlled, randomised, multi-centre trial comparing imlifidase and standard-of-care with standard-of-care alone in the treatment of	Innere Medizin III_716	Oberbauer Rainer

	severe anti-GBM antibody disease (Goodpasture disease)		
FA716C1024	A Phase 2, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Assess the Safety, Efficacy, and Tolerability of ARGX-117 in Improving Allograft Function in Recipients of a Deceased Donor Renal Allograft at Risk for Delayed Graft Function	Innere Medizin III_716	Oberbauer Rainer
FA716C1025	A prospective, post-authorisation long-term follow-up trial of patients previously treated with imlifidase prior to kidney transplantation, including a non-comparative concurrent reference cohort", protocol number 20-HMedIdeS-20	Innere Medizin III_716	Oberbauer Rainer
FA716C2505	A multi-modal assessment of immunosuppressive drug non-adherence in kidney transplant recipients	Innere Medizin III_716	Bond Gregor
FA716D0722	A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older with Active Idiopathic Inflammatory Myopathy	Innere Medizin III_716	Scheinecker Clemens
FA716D0723	A Multicenter, Randomized, Parallel-group, Double-blind, Two-arm, Phase III Study to Evaluate the Safety and Efficacy of Anifrolumab Compared with Placebo in Male and Female Participants 18 to 70 Years of	Innere Medizin III_716	Scheinecker Clemens

	Age Inclusive with Systemic Sclerosis (DAISY)		
FA716D0724	“A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy”	Innere Medizin III_716	Scheinecker Clemens
FA716D0812	EU Horizon - Maximising Impact of Prescription Drugs in Rheumatoid Arthritis	Innere Medizin III_716	Aletaha Daniel
FA716D2401	EmpowerRA: RheumaBuddy	Innere Medizin III_716	Nakhost Lotfi Nasim
FA716E0961	“A Pilot Open Label, Multi-dose, Phase 2 Study to Assess Changes in a Novel Histological Activity Scale in Response to ARO-AAT in Patients with Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)	Innere Medizin III_716	Trauner Michael
FA716E0968	WO41535 - A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) PLUS BEVACIZUMAB VERSUS ACTIVE SURVEILLANCE AS ADJUVANT THERAPY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA AT HIGH RISK OF RECURRENCE AFTER SURGICAL RESECTION OR ABLATION	Innere Medizin III_716	Trauner Michael
FA716E0984	Elimination of Hepatitis C in Eastern Austria	Innere Medizin III_716	Trauner Michael
FA716E1005	Prospective, non-interventional, observational study in patients with IBD receiving IV or SC vedolizumab therapy to observe route of administration choices and outcomes (VARIETY-AUT)	Innere Medizin III_716	Trauner Michael

FA716E1008	A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis	Innere Medizin III_716	Trauner Michael
FA716E1021	Prediction of endoscopic features of disease from single-cell RNA sequencing data in sigmoid colon of patients with ulcerative colitis	Innere Medizin III_716	Trauner Michael
FA716E1049	A 14-Week Phase 2b, Randomized, Double-Blind, Dose-Ranging Study to Determine the Pharmacokinetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult Patients with Moderate to Severe Ulcerative Colitis or Crohn's Disease (RELIEVE UCDD)	Innere Medizin III_716	Trauner Michael
FA716E1050	Österreichweites nationales HCC Register	Innere Medizin III_716	Trauner Michael
FA716E1051	A Phase 3, randomized, double-blind, placebo-controlled program to evaluate the efficacy and safety of MK-7240 in participants with moderately to severely active ulcerative colitis	Innere Medizin III_716	Trauner Michael
FA716E1052	Diagnostic and prognostic utility of spleen stiffness measurement by vibration-controlled transient elastography (100 Hz probe) in advanced chronic liver disease – a prospective multicenter study	Innere Medizin III_716	Trauner Michael
FA716E1053	A 24-Week, Phase 2b, Randomized, Double-Blind Long-Term Extension Study to Evaluate Pharmacokinetics, Efficacy Safety, and Tolerability of TEV-48574 in Adult Patients with Moderate to Severe Ulcerative Colitis or Crohn's Disease who completed the treatment phase of the Dose-	Innere Medizin III_716	Trauner Michael



	Ranging Study (RELIEVE UCCD LTE)		
FA716E1054	A Prospective, Post-marketing, non-interventional study of RISankizumab evaluating real-world clinical Effectiveness in Crohn's disease (APPRISE)	Innere Medizin III_716	Trauner Michael
FA716E1055	A Phase 2, Randomized, Double-Blind, PlaceboControlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Ulcerative Colitis	Innere Medizin III_716	Trauner Michael
FA716E1056	A randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety of ABX464 once daily for induction treatment in patients with moderate to severely active ulcerative colitis	Innere Medizin III_716	Trauner Michael
FA716E1057	A phase II, double-blind, randomised, placebo-controlled trial to evaluate the efficacy and tolerability of ZED1227 in celiac disease subjects experiencing symptoms despite gluten-free diet (CEC-013/CEL)	Innere Medizin III_716	Trauner Michael
FA716E1058	A randomized, double-blind, multicenter phase III study to evaluate the long-term efficacy and safety of ABX464 25 mg or 50 mg once daily as a maintenance therapy in subjects with moderately to severely active ulcerative colitis	Innere Medizin III_716	Trauner Michael

FA716E1059	A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 2 Active Dose Regimens of MORF-057 in Adults with Moderately to Severely Active Crohn's Disease (GARNET)"	Innere Medizin III_716	Trauner Michael
UE71606013	Ludwig Boltzmann Institut für Arthritis und Rehabilitation	Innere Medizin III_716	Bonelli Michael
UE71606013	Ludwig Boltzmann Institut für Arthritis und Rehabilitation	Innere Medizin III_716	Bonelli Michael
FA781B1908	Retrospektive Datenanalyse von Kindern und Jugendlichen unter Fycompa Therapie bezüglich Therapiedauer, Effektivität und Safety Daten	Kinder- und Jugendheilkunde_781	Feucht Martha
FA781B2802	Combating Viral Susceptibility in Premature Infants	Kinder- und Jugendheilkunde_781	Wisgrill Lukas
FA781B3201	Dissecting the Pathogenic mechanisms in central nervous system high-grade neuroepithelial tumors with BCOR-alteration (CNS HGNET-BCOR)	Kinder- und Jugendheilkunde_781	Gojo Johannes Salomon
FA781B3204	Feasibility study of a tumor board software to facilitate a supraregional pediatric precision oncology CNS tumor board	Kinder- und Jugendheilkunde_781	Gojo Johannes Salomon
FA781B3207	Targeting DNA damage response to eradicate ependymoma persister cells (DEEpend)	Kinder- und Jugendheilkunde_781	Gojo Johannes Salomon
FA781B3208	Deciphering driver mechanisms of oncofusions in aggressive, rare pediatric brain tumors	Kinder- und Jugendheilkunde_781	Gojo Johannes Salomon
FA781B3506	A registry of patients treated with Fintepla	Kinder- und Jugendheilkunde_781	Male-Dressler Anastasia
FA781F1006	FH-Register - Familiäre Hypercholesterinämie	Kinder- und Jugendheilkunde_781	Greber-Platzer Susanne
FA781F1009	Eine offene Studie zur Untersuchung der Langzeitsicherheit und Wirksamkeit von Evinacumab bei Patienten mit homozygoter familiärer Hypercholesterinämie	Kinder- und Jugendheilkunde_781	Greber-Platzer Susanne

FA781F1205	Rare disease, more rare diagnosis: Mapping the accuracy of laboratory screening for rare bone disorders in Austria	Kinder- und Jugendheilkunde_781	Raimann Adalbert
FA781F1601	Newborn Screening for Spinal Muscular Atrophy in Austria	Kinder- und Jugendheilkunde_781	Zeyda Maximilian
FA781F1602	Pilot for Austrian SMA Newborn Screening	Kinder- und Jugendheilkunde_781	Zeyda Maximilian
FA781F1905	Education & Care in RARE	Kinder- und Jugendheilkunde_781	Vodopiutz Julia
FA781F2201	Writing Grant for Pediatric HoFH research with evinacumab	Kinder- und Jugendheilkunde_781	Nigmann Charlotte
FA781G0801	SysDOC – Systematische digitale Dokumentation und Analyse von electronic patient-reported Outcomes (ePROs) bei Kindern und Jugendlichen mit chronischen Erkrankungen	Kinder- und Jugendheilkunde_781	Eibensteiner Fabian
FA781G0902	SaroMyrD4FSGS	Kinder- und Jugendheilkunde_781	Daniel-Fischer Lisa
FW781B0201	Gut-immune-brain axis dysfunction in premature neonates	Kinder- und Jugendheilkunde_781	Wisgrill Lukas
UE78106007	OKids	Kinder- und Jugendheilkunde_781	Greber-Platzer Susanne
UE78106024	Diagnostik_Sprachentwicklungsstörung	Kinder- und Jugendheilkunde_781	Greber-Platzer Susanne
FA765A0502	Entwicklung eines Online-Selbsthilfeprogramms zur Suizidprävention bei Kindern und Jugendlichen	Kinder- und Jugendpsychiatrie_765	Akkaya-Kalayci Türkan
FA765A0503	Entwicklung eines Online-Selbsthilfeprogrammes zur Suizidprävention bei Kindern und Jugendlichen	Kinder- und Jugendpsychiatrie_765	Akkaya-Kalayci Türkan
FA765A0801	Suizidalität Und Selbstverletzendes Verhalten: Hinschauen und Intervenieren	Kinder- und Jugendpsychiatrie_765	Plener Paul
FA765A0805	Jugendvertrauenspersonen Stärken Hilfebedarf Erkennen Lehrlingsgesundheit Prägen	Kinder- und Jugendpsychiatrie_765	Plener Paul
UE76506003	Digitale Gesundheitsanwendung in der Kinder- und Jugendpsychiatrie - Phase II	Kinder- und Jugendpsychiatrie_765	Kothgassner Oswald
UE76506004	Home Treatment 2	Kinder- und Jugendpsychiatrie_765	Plener Paul

FA729A0168	A Two-Period, Randomised, Cross-over Study in Healthy Subjects to investigate the pharmacokinetic and pharmacodynamic equivalence and safety of two different recombinant tPA presentations (PBS-tPA versus Actilyse®), at low and high subtherapeutic doses in the ascending part of the dose-response curve	Klinische Pharmakologie_729	Jilma Bernd
FA729A0169	A Phase 1b, Open-label, single-arm study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical effect of ANX1502 in participants with primary cold agglutinin disease	Klinische Pharmakologie_729	Jilma Bernd
FA729A0170	Open-label study to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of Povetacicept in subjects with autoimmune cytopenias (RUBY-4)	Klinische Pharmakologie_729	Jilma Bernd
FA729A0266	A Phase 1/2, Randomized, Single-blind, Placebo-controlled, Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD9550 in Overweight and Obese Participants with Type 2 Diabetes Mellitus	Klinische Pharmakologie_729	Wolzt Michael
FA729A0267	A phase 1 study of PluPHPVE6E7 immunotherapy in patients with HPV-16-associated oropharyngeal squamous cell carcinoma	Klinische Pharmakologie_729	Wolzt Michael
FA729A1031	Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors (RespiriTb)	Klinische Pharmakologie_729	Zeitlinger Markus

FA729A1034	Novel Gram-Negative Antibiotic Now (GNA NOW)	Klinische Pharmakologie_729	Zeitlinger Markus
FA729A1045	VACCELERATE - European Corona Vaccine Trial Accelerator Platform	Klinische Pharmakologie_729	Zeitlinger Markus
FA729A1104	Effects of VGA039, a monoclonal protein S antibody, on ex vivo blood coagulation of healthy volunteers and of adult and pediatric patients with hemophilia A, hemophilia B and von Willebrand's disease	Klinische Pharmakologie_729	Schörghofer Christian
FA729A1404	Quantitative evaluation of the brain distribution and pharmacokinetics of isavuconazole using positron emission tomography (PET) imaging	Klinische Pharmakologie_729	Langer Claus Oliver
FA729A1803	Investigating the Genotypic and Phenotypic Properties of ATCC-29213 Quality Control Strain in Ten European Laboratories	Klinische Pharmakologie_729	Nussbaumer-Pröll Alina
FA729A2201	Comparison of the immune response after LPS ex vivo stimulation of whole blood with and without cefiderocol	Klinische Pharmakologie_729	Pracher Lena Maria
FA729A2301	Effect of Cefepime/Enmetazobactam (FEP/META), a novel b-Lactamase Inhibitor (ADVANZ PHARMA) or Ceftazidime/Avibactam (CAZ-AVI) and its combinations with Aztreonam (ATM) against clinical isolates, resistant for different Betalactamase classes	Klinische Pharmakologie_729	Al Jalali Valentin
UE79406002	Nationales Referenzzentrum für Gesundheitssystem-assoziierte Infektionen und Krankenhaushygiene	Krankenhaushygiene und Infektionskontrolle_794	Presterl Elisabeth
FA712A0306	Early Stage: Combination of Artemisinin with 5-ALA/heme biosynthesis modulators as novel therapy for brain tumors and other cancers	Krebsforschung_712	Berger Walter

FA712A0307	Personalized Drug Screening for Hematological Malignancies: 3D human bone marrow models with patient-derived cells	Krebsforschung_712	Berger Walter
FA712A0709	EU Twinning to skyrocket scientific excellence towards individual radiosensitivity prediction by raising the bar in knowledge transfer, networking, and technological innovation in radiobiology	Krebsforschung_712	Knasmüller Siegfried
FA712A2003	ME/CFS Lines A multidisciplinary consortium and biobank for unravelling ME/CFS aetiology in Lifelines - Consortium project	Krebsforschung_712	Vogl Thomas
FA712A2004	Disentangling the contribution of the microbiota-immune axis to long-COVID via high throughput serology of population scale cohorts	Krebsforschung_712	Vogl Thomas
FA712A2101	Multiscale discovery of cellular and microanatomical determinants of metastasis	Krebsforschung_712	Winkler Juliane
FW712A0301	Defense Mechanisms during Microbial Hair Follicle Invasion	Krebsforschung_712	Bauer Thomas
FW712A0401	Securing Host Immunity: Elimination versus Destruction	Krebsforschung_712	Sibilia Maria
FA793A0811	SelfAmps facilitating resolution of inflammation in atherosclerosis	Labormedizin_793	Binder Christoph
FA793A1901	BBMRI.at Phase 2	Labormedizin_793	Haslacher Helmuth
FA793A1904	Material Transfer Clickmer Systems for IVD-Performance Evaluation	Labormedizin_793	Haslacher Helmuth
FA793A1905	Alpha-1 sample analysis	Labormedizin_793	Haslacher Helmuth
FA793A2003	Exploiting the anti-cancer antibody response in MPN patients and mouse models for the development of new immunotherapeutics	Labormedizin_793	Kralovics Robert
FA793A2102	checkit!	Labormedizin_793	Luf Anton
FA793A2802	Swedish Research Council	Labormedizin_793	Penninger Josef
FA793A2803	Swept Lasers for non-invasive diagnostics	Labormedizin_793	Penninger Josef

FA793A2804	Modern approaches for developing antivirals against SARS-CoV 2	Labormedizin_793	Penninger Josef
FA793A2804	Modern approaches for developing antivirals against SARS-CoV 2	Labormedizin_793	Penninger Josef
FA793B0120	Analyse des vaginalen Mikrobioms (inkl. Mykobiom) im Therapieverlauf einer Scheideninfektion	Labormedizin_793	Willinger Birgit
FA793B0121	Sensititre™ Susceptibility Plates 510k Clinical Trial for Breakpoint Compliance	Labormedizin_793	Willinger Birgit
FA793B0501	Sensitivity of rapid diagnostic tests for malaria caused by P. falciparum and prevalence of histidine-rich protein gene deletion as cause of failure in several African countries (AFRI-MECA)	Labormedizin_793	Lötsch Felix
FW793A0101	Sialoproteome driven immune response in breast cancer	Labormedizin_793	Mereiter Stefan
FW793A0201	Extracellular Vesicles in Inflammation DFH 54-B	Labormedizin_793	Binder Christoph
FA616A1003	Understanding of the Membrane Connection Linking the Nucleus to the Endoplasmic Reticulum	Max Perutz Labs_305	Otsuka Shotaro
FW618A0102	The role of Ashwin in pre-tRNA processing and (m)RNA export	Max Perutz Labs_305	Martinez Javier Augusto
FA632A0508	Diagnostic HER2DX-guided treatment for patients with early-stage HER2-positive breast cancer	Medical Data Science_303	Ristl Robin
FA632A0606	Does the ERAS program implementation change the rate of nutrition therapy use? A nutritionDay analysis 2006-2023	Medical Data Science_303	Hiesmayr Jörg Michael
FA632A0607	Analyse und Bewertung der Ernährungssituation und Qualität der Ernährungsversorgung in Krankenhäusern und in stationären Altenpflegeeinrichtungen	Medical Data Science_303	Hiesmayr Jörg Michael

FA660A1502	Schätzung eines statistischen Modells für die Ableitung von Alters-, Geschlechts- und Schulbildungs-abhängigen z-scores (Standard deviation scores) für eine Variable aus dem psychometrischen Test VVT 3.0.	Medical Data Science_303	Gleiss Andreas
FA660A1901	TOWARDS PRECISE STATISTICAL ANALYSIS PLANS FACILITATING MICRODATA ANALYSES TO ADVANCE HEALTH RESEARCH	Medical Data Science_303	Dunkler Daniela
FW631A0101	FG 9-N	Medical Data Science_303	Bogunovic Hrvoje
UE60206002	Präzisionsmedizin bei Arthrose: Nutzung von KI für patientenindividuelle Vorhersagen, Monitoring und Behandlungsansätzen	Medical Data Science_303	Ritschl Valentin
FA616A0402	EU H2020 The Nuclear Pore Basket – Functional Architecture of a Membrane Remodeling Machine	Medizinische Biochemie_305	Köhler Alwin
FA616A0403	Phasenseparierte Lipidroplets als Zentrum für nukleare Proteinqualitätskontrolle	Medizinische Biochemie_305	Köhler Alwin
FA616A0901	Regulationsmechanismen von Stressgranule Bildung und Auflösung	Medizinische Biochemie_305	Karagöz Gülsün Elif
FA618A0210	Rom1 as a fungal sensing factor during skin colonization of the human fungal pathogen Candida auris	Medizinische Biochemie_305	Phan Canh Trinh
FA605A1906	TEXTile integrated HYbrid Printed Electronics	Medizinische Physik und Biomedizinische Technik_340	Moscato Francesco
FA605A2206	MTF	Medizinische Physik und Biomedizinische Technik_340	Figl Michael
FA605A2207	Ultraschall	Medizinische Physik und Biomedizinische Technik_340	Figl Michael
FA605A2208	Ultraschall	Medizinische Physik und Biomedizinische Technik_340	Figl Michael
FA605A2301	Coating of Neurovascular Stents	Medizinische Physik und Biomedizinische Technik_340	Grasl Christian



FA605A2303	Blood Trauma testing of an axial pump	Medizinische Physik und Biomedizinische Technik_340	Schima Heinrich
FA605A2602	Switchable magneto-plasmonic contrast agents and molecular imaging technologies	Medizinische Physik und Biomedizinische Technik_340	Drexler Wolfgang
FA605A3003	Material Transfer Agreement	Medizinische Physik und Biomedizinische Technik_340	Rausch Ivo
FA605A3004	EU COST Action Radionuclide theragnostics for personalised medicine	Medizinische Physik und Biomedizinische Technik_340	Rausch Ivo
FA605A3601	Safe Vascular Access Needle	Medizinische Physik und Biomedizinische Technik_340	Oberoi Gunpreet
FA605A3701	Neurohabilitation FES	Medizinische Physik und Biomedizinische Technik_340	Nguyen Quang
FA736A0301	Onko AI	Neurochirurgie_736	Dorfer Christian
FA736A0801	Evaluation of Sutability of Cold Ablation Robot Guided Laser Osteotomy for Stereoelectroencephalography (SEEG) Surgical Procedures in Sheep	Neurochirurgie_736	Rössler Karl
FA761A0207	Gesundes Altern	Neurologie_761	Beisteiner Roland
FA761A1123	1.) Serum Neurofilament light chains as a marker for neurological manifestation in Fabry Disease 2.) Neuroinflammation in Fabry Disease and Gaucher Disease: histopathological examination in human brains	Neurologie_761	Berger Thomas
FA761A1165	Double-blind, randomized, sham-controlled study of closed-loop repetitive transcranial magnet stimulation (rTMS) for the short-term prevention of migraine.	Neurologie_761	Berger Thomas
FA761A1166	Eine randomisierte, doppelblinde, placebokontrollierte, parallele, multizentrische Phase-III-Studie zur Beurteilung der Sicherheit und Wirksamkeit von ALXN1720 bei ERwachsene3n mit	Neurologie_761	Berger Thomas

	generalisierter Myasthenia Gravis		
FA761A1167	A multicenter prospective longitudinal study of clinical outcomes, disease course, health-related quality of life and health care resource utilization in adult patients with multivocal motor neuropathy	Neurologie_761	Berger Thomas
FA761A1168	Multicenter, multinational, natural history study in participants with DOK7 congenital myastenic syndroms	Neurologie_761	Berger Thomas
FA761A1169	An interventional, phase 3 extension study to investigate long-term safety and tolerability of tolebrutinib in participants with relapsing multiple sclerosis, primary progressive multiple sclerosis or nonrelapsing secondary progressive multiple sclerosis	Neurologie_761	Berger Thomas
FA796A0117	Joint Action on integration of ERNs into national healthcare systems	Neurologie_761	Voigtländer Till
FA796A0503	Decoding cellular senescence in glioblastoma	Neurologie_761	Wöhler Adelheid
FA796A0705	Projekt FO999915194: Histologie	Neurologie_761	Amberg Nicole
FA796A0706	Projekt FO999913849: Histologie	Neurologie_761	Amberg Nicole
FA796A0707	Projekt FO999915193: Histologie	Neurologie_761	Amberg Nicole
FA796A0708	Projekt FO999913848: Histologie	Neurologie_761	Amberg Nicole
FA761A1114	Biomarker in early and preclinical neurological phase of Gaucher's disease	Neurologie-Klinik_761	Berger Thomas
FA728A1302	Prospective Evaluation of the European Society of Cardiology 0/1h-algorithm's Safety and Efficacy for Triage of Patients with Suspected Myocardial Infarction	Notfallmedizin_728	Roth Dominik

FA728A1303	Digitalisierung medizinischen Wissens als Basis für intelligente Lösungen für die Hämato-Onkologie und Notfallmedizin	Notfallmedizin_728	Roth Dominik
FA728A1503	Chest Compression Synchronized Ventilation (CCSV) - Eine explorative klinische Nachverfolgung nach Markteinführung	Notfallmedizin_728	Schnaubelt Sebastian
UE72806002	Machbarkeitsstudie: Digitale Notfallversorgung für Pflegeheim-Bewohner:innen	Notfallmedizin_728	Schreiber Wolfgang
FA737A0609	Allofit IT with HXPE in Total Hip Arthroplasty	Orthopädie und Unfallchirurgie_739	Windhager Reinhard
FA737A1204	Ausbildungsstipendium	Orthopädie und Unfallchirurgie_739	Tögel Stefan
FA737A2003	Fellowship: Grundlagen des Strahlenschutzes	Orthopädie und Unfallchirurgie_739	Benca Emir
FA737B0201	In-vivo Testung einer magnesiumbasierten, intramedullären Spannosteosynthese im Kaninchenmodell	Orthopädie und Unfallchirurgie_739	Hajdu Stefan
FA608A0330	FEQUANT 4	Pathobiochemie und Genetik_306	Scheiber-Mojdehkar Barbara
FA608A0331	FEQUANT 1	Pathobiochemie und Genetik_306	Scheiber-Mojdehkar Barbara
FA608A0332	FEQUANT 2	Pathobiochemie und Genetik_306	Scheiber-Mojdehkar Barbara
FA608A0333	FEQUANT 5	Pathobiochemie und Genetik_306	Scheiber-Mojdehkar Barbara
FA608A0334	FEQUANT 6	Pathobiochemie und Genetik_306	Scheiber-Mojdehkar Barbara
FA608A0335	FEQUANT 3	Pathobiochemie und Genetik_306	Scheiber-Mojdehkar Barbara
FA681A0105	Health risk of emerging concern: PFAS in the urban water cycle	Pathobiochemie und Genetik_306	Gundacker Claudia
FA681A0601	FFG Schülerpraktikum Alessandro Rodia 2024: snoRNAs in der Haut	Pathobiochemie und Genetik_306	Schösserer Markus

FW681A0301	Understanding Nuclear Metabolic Dynamics in Regeneration	Pathobiochemie und Genetik_306	Miller Anne Elisabeth
FA791A0719	A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation"	Pathologie_791	Müllauer Leonhard
FA791A1016	Tissue Sample acquisition and analysis for biomarker development	Pathologie_791	Kain Renate
FA791A1020	A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)	Pathologie_791	Kain Renate
FA791A1021	The purpose of the grant is to support the Banff Working Group for TMA in renal TX	Pathologie_791	Kozakowski Nicolas
FA791A1025	A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis	Pathologie_791	Kain Renate
FA791A1034	A phase 1 study of FluBHPVE6E7 immunotherapy in patients with HPV16-associated oropharyngeal squamous cell carcinoma	Pathologie_791	Kain Renate

FA791A1035	A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of MK-7684A Versus Pembrolizumab as Adjuvant Treatment in Participants with Resected High-risk Stage II-IV Melanoma (KEYVIBE-010)	Pathologie_791	Kain Renate
FA791A1036	A Randomised Phase III Open Label Study of regorafenib + nivolumab vs standard chemotherapy in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)	Pathologie_791	Kain Renate
FA791A1037	A phase Ib/II single-arm, multicenter study of sacituzumab-govitecan, a TROP-2 targeting antibody linked with SN38, for patients with metastatic esophagogastric adenocarcinoma	Pathologie_791	Kain Renate
FA791A1133	A PROSPECTIVE, OPEN-LABEL, MULTICENTRE PHASE-II-TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ZANUBRUTINIB (BGB-3111), A BTK INHIBITOR, PLUS TISLELIZUMAB (BGB-A317), A PD-1 INHIBITOR, FOR TREATMENT OF PATIENTS WITH RICHTER TRANSFORMATION	Pathologie_791	Simonitsch-Klupp Ingrid
FA791A1135	Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy	Pathologie_791	Simonitsch-Klupp Ingrid
FA791A1421	CA209-8Y8: A Phase 3b, Randomized, Double-blind Study of Nivolumab Combined with Ipilimumab versus Nivolumab Monotherapy for Patients with Previously Untreated Advanced Renal Cell Carcinoma and	Pathologie_791	Haitel Andrea

	Intermediate- or Poor-Risk Factors		
FA791A1427	A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette-Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)	Pathologie_791	Haitel Andrea
FA791A1626	ABCSG 45: A prospective, open, randomized, phase II study of carboplatin/ olaparib in the pre-operative treatment of patients with triple-negative primary breast cancer which exhibit the features of positive homologous recombination deficiency (HRD) status Zentrum Prof. Singer	Pathologie_791	Bago-Horvath Zsuzsanna
FA791A1627	ABCSG 45: A prospective, open, randomized, phase II study of carboplatin/ olaparib in the pre-operative treatment of patients with triple-negative primary breast cancer which exhibit the features of positive homologous recombination deficiency (HRD) status Zentrum Prof. Steger	Pathologie_791	Bago-Horvath Zsuzsanna
FA791A1628	45 Studie mit dem Studientitel „A prospective, open, randomized, phase II study of carboplatin/ olaparib in the pre-operative treatment of patients with triple-negative primary breast cancer which exhibit the features of positive homologous recombination deficiency (HRD) status“	Pathologie_791	Bago-Horvath Zsuzsanna

FA791A1657	CAMBRIA-1: „A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degradar) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence”	Pathologie_791	Bago-Horvath Zsuzsanna
FA791A1658	A MULTICENTER, SINGLE-ARM, THREE COHORT, PHASE II TRIAL OF PATRITUMAB DERUXTECAN (HER3-DXD) IN PATIENTS WITH ACTIVE BRAIN METASTASES FROM METASTATIC BREAST CANCER AND NON-SMALL CELL LUNG CANCER, AND IN PATIENTS WITH LEPTOMENINGEAL CARCINOMATOSIS FROM ADVANCED SOLID TUMORS (The TUXEDO-3 Study)	Pathologie_791	Bago-Horvath Zsuzsanna
FA791A1659	CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degradar) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease ”	Pathologie_791	Bago-Horvath Zsuzsanna

FA791A1660	CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degradar) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease	Pathologie_791	Bago-Horvath Zsuzsanna
FA791A1661	“A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2-Negative (HER2-) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH-]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy”	Pathologie_791	Bago-Horvath Zsuzsanna
FA791A1662	A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (MK-2870-005/ENGOT-en23/GOG-3095)	Pathologie_791	Bago-Horvath Zsuzsanna



FA791A2113	“A randomized, double-blind, placebo-controlled, 2-arm Phase III study to assess efficacy and safety of xevinapant and radiotherapy compared to placebo and radiotherapy for demonstrating improvement of disease-free survival in participants with resected squamous cell carcinoma of the head and neck, who are at high risk for relapse and are ineligible for high-dose cisplatin“	Pathologie_791	Pammer Johannes
FA791A2604	A Phase 1b Study Evaluating the Safety and Efficacy of AMG 757 in Combination with AMG 404 in Subjects with Small Cell Lung Cancer (SCLC)	Pathologie_791	Kain Renate
FA791A3412	MULTi-Tumour based prediction and manipulation of Immune Response	Pathologie_791	Comperat Eva Maria
FA791A3413	A retrospective chart review of real-world treatment outcomes in patients with locally advanced unresectable or metastatic urothelial cancer based on HER2 expression	Pathologie_791	Comperat Eva Maria
FA791A3414	“ An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy with in Subjects with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma that Expresses HER2 (IHC 1+ and Greater)”	Pathologie_791	Comperat Eva Maria
FA791A3415	A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2	Pathologie_791	Comperat Eva Maria

FA791A3416	An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617) versus Observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen (PSMA) positive Oligometastatic Prostate Cancer (OMPC)“	Pathologie_791	Comperat Eva Maria
FA791A3602	“Double-blind, randomised, placebo-controlled, phase IIb trial on the efficacy and safety of norursodeoxycholic acid tablets in patients with non-alcoholic steatohepatitis (NASH)“	Pathologie_791	Kain Renate
FA623A0512	Sustainable Strategy Toward Adopting Inovative Diagnostics for managing and controlling tropical diseases in Burkina Faso (SUSTAIN-Diagnostics)	Pathophysiologie, Infektiologie und Immunologie_370	Walochnik Julia
FA623A0803	Etablierung eines molekularen Nachweises von subadulten Sandmückenstadien aus Bodenproben	Pathophysiologie, Infektiologie und Immunologie_370	Kniha Edwin
FA623A0901	EU H2021 Immunomodulatory properties of L. plantarum extracellular vesicles in airway allergy	Pathophysiologie, Infektiologie und Immunologie_370	Schabussova Irma
FA624A0218	Pilot Study for Profiling the specificities of fully human polyclonal ATG from Transchromosomic Bovines	Pathophysiologie, Infektiologie und Immunologie_370	Steinberger Peter
FA624A0603	Projekt FO999919316 T Helfer Zellen	Pathophysiologie, Infektiologie und Immunologie_370	Boucheron Nicole
FA624A0604	Projekt FO999919317: T Helfer Zellen	Pathophysiologie, Infektiologie und Immunologie_370	Repic Anna
FA644A0112	Entwicklung von Azithromycin-Derivaten zur medikamentösen Behandlung von Infektionen durch SARS-CoV-2 und anderen behüllten Viren	Pathophysiologie, Infektiologie und Immunologie_370	Stockinger Hannes

FA644A0508	Ein quantitatives Konzept zur Untersuchung human-assoziiertes Antibiotikaresistenzen in Flüssen entlang des humanen Abwasserpfades	Pathophysiologie, Infektiologie und Immunologie_370	Kirschner Alexander
FA644A1001	Unraveling the Detrimental Role of Bystander CD8+ T cells in Cachexia	Pathophysiologie, Infektiologie und Immunologie_370	Richter Felix
FA648A0318	Allergen- and virus-specific antibody profiling within the LEAD Study	Pathophysiologie, Infektiologie und Immunologie_370	Valenta Rudolf
FA648A0617	Development of seed-derived nutraceuticals for the treatment of obesity and related disorders and its combined effects with a high intensity interval training protocol (NUTRISEEDEX)	Pathophysiologie, Infektiologie und Immunologie_370	Pietschmann Peter
FA648A1024	Green Histology - Praktika für Schüler:innen 2024	Pathophysiologie, Infektiologie und Immunologie_370	Ellinger Isabella
FA648A1025	Green Histology - Praktika für Schüler:innen 2024	Pathophysiologie, Infektiologie und Immunologie_370	Ellinger Isabella
FA648A2005	Live Cell Cytometry	Pathophysiologie, Infektiologie und Immunologie_370	Schepelmann Martin
FA648A2302	Systems immunology in immuno-oncology	Pathophysiologie, Infektiologie und Immunologie_370	Mechtcheriakova Diana
FA648A2304	LymphoidStructureMiner: AI-based exploration of the immunological contexture of lymphoid structures in translational research	Pathophysiologie, Infektiologie und Immunologie_370	Mechtcheriakova Diana
FW624A0101	Rolle von PATZ1 für CD8+ Gedächtnis-T-Zell-Differenzierung	Pathophysiologie, Infektiologie und Immunologie_370	Sakaguchi Shinya
FW644A0201	Devising Advanced TCR-T cells to eradicate OsteoSarcoma	Pathophysiologie, Infektiologie und Immunologie_370	Huppa Johannes
FW648A0101	Memory B cells during repeated antigen exposure	Pathophysiologie, Infektiologie und Immunologie_370	Grimsholm Ola
UE64806005	Systems biology research in immuno-oncology	Pathophysiologie, Infektiologie und Immunologie_370	Mechtcheriakova Diana

FA726A0701	Evaluierung BVAEB-Gesundenuntersuchung Gesundheit und Beruf (GuB)	Physikalische Medizin, Rehabilitation und Arbeitsmedizin_726	Steiner Margarete
FA621A0802	Understanding pancreas biology with AI/ML	Physiologie und Pharmakologie_350	Slak Rupnik Marjan
FA625A1003	Multifaktorielle Fluoreszenzmikroskopie und KI-unterstützte Analyse von Blutaussstrichen mit Fokus Entzündungsdiagnostik	Physiologie und Pharmakologie_350	Schmid Johannes
FA625A1106	Loop Immunmodulation;LOOP LAB evaluation in small animal models	Physiologie und Pharmakologie_350	Schabbauer Gernot
FA625A1106	Loop Immunmodulation;LOOP LAB evaluation in small animal models	Physiologie und Pharmakologie_350	Schabbauer Gernot
FA641A0117	Aktivierung von Gs-gekoppelte EP2- Rezeptoren	Physiologie und Pharmakologie_350	Zebedin-Brandl Eva Maria
FA641A1105	LS19-019 STAT3 Isoformen in hämatopoetischen Erkrankungen	Physiologie und Pharmakologie_350	Casanova Emilio
FA641A1501	Pharmakologische Stimulation von Blutstammzellen mit Fokus auf den Calcium-sensing Rezeptor	Physiologie und Pharmakologie_350	Zebedin-Brandl Eva Maria
FW641A0101	The role of phosphorylation in organic cation transporter 3	Physiologie und Pharmakologie_350	Yang Jae-Won
FW641A0201	TRPV6 regulation by sensing PIP2 in the paralipidome	Physiologie und Pharmakologie_350	Stockner Thomas
FW641A0301	GR: Oncosuppressor in KRAS driven lung cancer	Physiologie und Pharmakologie_350	Moll Herwig
FW641A0401	HOMA-homoamphetamine derivatives as partial releasers	Physiologie und Pharmakologie_350	Sitte Harald
FW683A0101	Impact Of Gestational Immune Activation On The Female Brain	Physiologie und Pharmakologie_350	Pollak-Monje Quiroga Daniela
UE64106001	Collaboration Agreement AL-Ahliyya Amman University Amman-Jordan	Physiologie und Pharmakologie_350	Sitte Harald
FA734A0101	Erhöhung der Adhärenz von Spalthauttransplantaten über Gelenken durch Reduktion von Reibung und Scherkräften via Lokaltherapeutika	Plastische, Rekonstruktive und Ästhetische Chirurgie_734	Supper Paul
FA734A0201	SILKVISION (spider silk for restoration of impaired vision) Pathfinder Preparation Project	Plastische, Rekonstruktive und Ästhetische Chirurgie_734	Stadlmayr Sarah

FW734A0101	How tumor cells could rescue Schwann cells from chronic denervation-induced senescence	Plastische, Rekonstruktive und Ästhetische Chirurgie_734	Weiss Tamara
FA763B0802	EBRAINS 2.0: A Research Infrastructure to Advance Neuroscience and Brain Health	Psychiatrie und Psychotherapie_763	Lanzenberger Rupert
FA763B1301	Molekular-gezielte fokussierte transkraniale Ultraschall-Stimulation zur nicht-invasiven Neuromodulation von tiefen Hirnregionen	Psychiatrie und Psychotherapie_763	Godbersen Godber Mathis
FA763C0801	VOICE – Patient Involvement in Individuals with lived experience of Clinical High Risk for Psychosis	Psychiatrie und Psychotherapie_763	Hinterbuchinger Barbara
FA763C0802	PPIE EXPLORATION CALL: VOICE+ HOW TO TELL	Psychiatrie und Psychotherapie_763	Hinterbuchinger Barbara
FW763A0101	Wirksamkeit von Ketamin und Effekte auf neuropsychologische Funktionen bei Zwangsstörung unter Stress in einer Cross-Over Studie	Psychiatrie und Psychotherapie_763	Kraus Christoph
FA636A0407	Design-Reality-Gap Analyse der von Seiten der Stakeholder zur Verfügung gestellten telemedizinischen Tools für die Primärversorgung	Public Health_380	Hoffmann Kathryn
FA636A0408	Assessing healthcare for patients with post-acute infection syndromes and diseases including ME/CFS“, nachstehend „Forschungsprojekt“	Public Health_380	Hoffmann Kathryn
FA638A0601	Longitudinal Symptom Assessment in Dialysis Patients - A pilot study	Public Health_380	Hecking Manfred
FA646A0303	EU H2021 - ISIDORE	Public Health_380	Kutalek Ruth
FA646A0705	INTERACT Europe 100	Public Health_380	Grabovac Igor
FA646A0902	Qualitative und quantitative Studie zum Vorkommen von Female Genital Mutilation/Cutting (FGM/C) in Österreich	Public Health_380	Jirovsky-Platter Elena
FA646A1301	MigraCare - Einbindung von 24-Stunden-Betreuer:innen in Pflegenetzwerke in Österreich	Public Health_380	Wojczewski Silvia

FA646A1501	CoMitMenT: Co-Design-Strategien mit psychisch erkrankten Menschen zur körperlichen Gesundheitsförderung	Public Health_380	Schiffler Tobias
FA647A0518	Effekte hoch- und niederfrequenter elektromagnetischer Felder unter Berücksichtigung von Kombinationswirkungen mit krebserzeugenden Arbeitsstoffen - NIRMES	Public Health_380	Hutter Hans-Peter
FA669A0201	Schätzung und Verlauf der sozioökonomischen Heterogenität in der Lebensspanne auf Basis von VN-Todesanzeigen in Vorarlberg (1946-1981)	Public Health_380	Mayer Susanne
FA716C1503	Closing the Loop in Hemodialysis: A Precision Medicine Approach	Public Health_380	Hecking Manfred
FA716C1503	Closing the Loop in Hemodialysis: A Precision Medicine Approach	Public Health_380	Hecking Manfred
UE63806002	Vereinbarung für projektbezogene Unterstützung - Projekt Uricov	Public Health_380	Hecking Manfred
UE64606004	Nahda University of Beni Suef (NUB)	Public Health_380	Rieder Anita
CD10277105	CD-Laboratory for Patient-Centered Breast Imaging	Radiologie und Nuklearmedizin_771	Baltzer Pascal
FA771B0420	KLINISCHE STUDIE ZUR BEWERTUNG DER DIAGNOSTISCHEN GENAUIGKEIT DER KONTRASTVERSTÄRKTEN TOMOSYNTHESE IM VERGLEICH ZUR KONTRASTVERSTÄRKTEN MAMMOGRAPHIE	Radiologie und Nuklearmedizin_771	Helbich Thomas
FA771B0423	A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma	Radiologie und Nuklearmedizin_771	Attenberger Ulrike

FA771B0424	AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDE VERSUS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANTINELIGIBLE PARTICIPANTS WITH NEWLY-DIAGNOSED MULTIPLE MYELOMA	Radiologie und Nuklearmedizin_771	Attenberger Ulrike
FA771B0425	A Phase III, single arm, multicentre study to evaluate the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythaemia patients who are intolerant or refractory to or not eligible for other cytoreductive treatments	Radiologie und Nuklearmedizin_771	Helbich Thomas
FA771B0426	Phase 3 Study of Teclistamab in Combination with Lenalidomide versus Lenalidomide Alone in Participants with Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation.	Radiologie und Nuklearmedizin_771	Helbich Thomas
FA771B0502	Deciphering breast cancer heterogeneity and Tumor microenvironment with correlative imaging	Radiologie und Nuklearmedizin_771	Pinker-Domenig Katja
FA771B0861	Double-blind, randomised, Placebo-controlled Phase IIb Trial on the efficacy and safety of norursodeoxycholic acid tablets in patients with non-alcoholic steatohepatitis	Radiologie und Nuklearmedizin_771	Attenberger Ulrike

FA771B0864	A Phase 3, Multicenter, Open-Label, randomized Study to evaluate the efficacy and safety of Fedratinib compared to Best available Therapy in subjects with DIPS-Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and preciously treated with ruxolitinib (FREEDOM 2)	Radiologie und Nuklearmedizin_771	Attenberger Ulrike
FA771B0872	A Phase III Randomized, Double-Blind, Placebo-Controlled Study (URIROX-2)", protocol no. ALLN-177-302	Radiologie und Nuklearmedizin_771	Attenberger Ulrike
FA771B1311	A Multicenter, Randomized, Parallel-group, Doubleblind,Two-arm, Phase III Study to Evaluate the Safety and Efficacy of Anifrolumab Compared with Placebo in Male and Female Participants 18 to 70 Years of Age Inclusive with Systemic Sclerosis	Radiologie und Nuklearmedizin_771	Prosch Helmut
FA771B1401	A Randomized, Controlled, Open-Label, Phase 3 Study of Melflufen/Dexamethasone Compared with Pomalidomide/Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma who are Refractory to Lenalidomide	Radiologie und Nuklearmedizin_771	Attenberger Ulrike
FA771B1801	Gesundheitsförderliches wertschätzendes und wertschöpfendes Betriebsmanagement mit Fokus auf die Pensionsvorphase	Radiologie und Nuklearmedizin_771	Kirnbauer Isolde
FA771D0530	Phase 3, Randomized, Open-label,Study of Subcutaneous Nivolumab+ Relatlimab Fixed-dose Combination vs Intravenous Nivolumab+Relatlimab Fixed-dose Combination in Participants with Previously Untreated	Radiologie und Nuklearmedizin_771	Wolf Florian



	Metastatic or Unresectable Melanoma ("Trial).		
FA771D0531	Assessment of Long Term, Endovascular AAA Intervention using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis	Radiologie und Nuklearmedizin_771	Wolf Florian
FA771D0532	"Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator`s Choice in HLA-A*02:01-positive Patients with Previously Treated Advanced Melanoma (TEBE-AM)"	Radiologie und Nuklearmedizin_771	Wolf Florian
FA771D0901	CHANGE-MRI (CTEPH DIAGNOSIS Europe - MRI) - Phase-III diagnostic trial to demonstrate that functional lung MRI can replace VQ-SPECT in a diagnostic strategy for patients with suspected CTEPH where positive findings are verified with catheter pulmonary angiography or computed tomography pulmonary angiography (CPA/CTPA)	Radiologie und Nuklearmedizin_771	Beitzke Dietrich
FA771E0512	AcceleRating the Translation of virtual twins towards a pErsonalised Management of fatty llver patients	Radiologie und Nuklearmedizin_771	Langs Georg
FA771E0710	ENgineered CARtilage from Nose for the Treatment of Osteoarthritis	Radiologie und Nuklearmedizin_771	Trattnig Siegfried
FA771E1401	Validation of MR ChondralHealth-derived morphometric analysis and GLCM texture analysis using cadaver knees	Radiologie und Nuklearmedizin_771	Juras Vladimir

FA771E1901	A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years and older after an acute non-cardioembolic ischemic stroke or high-risk TIA", (OCEANIC-STROKE)	Radiologie und Nuklearmedizin_771	Marik Wolfgang
FA771G0225	Identifizierung von ED-B Fibronectin an Gewebeproben (Onkologie und Kardiovaskular) durch immunhistologische Aufarbeitung mit ED-B Affilin.	Radiologie und Nuklearmedizin_771	Hacker Marcus
FA771G0262	PSMAddition: An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)	Radiologie und Nuklearmedizin_771	Hacker Marcus
FA771G0279	"A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer"	Radiologie und Nuklearmedizin_771	Hacker Marcus
FA771G0281	07 "A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2-Negative (HER2-) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH-]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and	Radiologie und Nuklearmedizin_771	Hacker Marcus

	Have Received Endocrine Therapy”		
FA771G0282	„An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617) versus Observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen (PSMA) positive Oligometastatic Prostate Cancer (OMPC)“	Radiologie und Nuklearmedizin_771	Hacker Marcus
FA771G0401	Prosp. Phase-II-Studie. Neoadj. (177Lu)Lu-PSMAI&T-Radioligandentherapie für Patienten mit oligometast. Prostata-Ca, diagn. mit (68a)Ga-PSMA-11-PET-Bildgebung, gefolgt von radikaler Prostatektomie.	Radiologie und Nuklearmedizin_771	Rasul Sazan
UE77106001	Anstellung von 2 Ausbildungsärzte	Radiologie und Nuklearmedizin_771	Hacker Marcus
UE77106002	Anstellung von 1 Ausbildungsarzt	Radiologie und Nuklearmedizin_771	Helbich Thomas
FA774A0504	Usability und technische Funktionalität von ETD 2024	Radioonkologie_774	Lechner Wolfgang
FA774A1501	An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617) versus Observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen (PSMA) positive	Radioonkologie_774	Goldner Gregor

	Oligometastatic Prostate Cancer (OMPC)		
FA731T0504	A Phase III Prospective Multicenter Randomized Controlled Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered via the PARI Investigational eFlow Device plus Standard of Care versus Standard of Care Alone in the Treatment of Bronchiolitis Obliterans Syndrome in Patients post Double Lung Transplantation	Thoraxchirurgie_733	Jaksch Peter
FA733A0203	The use of extracorporeal photopheresis as immunomodulatory therapy of subclinical antibody-mediated rejection after lung transplantation: a prospective RCT	Thoraxchirurgie_733	Benazzo Alberto
FA733A0301	A double-blind, randomized, placebo-controlled study to assess the safety and efficacy of nebulized PC945 when added to systemic antifungal therapy for the treatment of refractory invasive pulmonary aspergillosis	Thoraxchirurgie_733	Jaksch Peter
FA733A0303	Austrosheld - Observational Study on the Clinical Use of Evusheld in immunocompromised patients (AZD7442) in Austria	Thoraxchirurgie_733	Jaksch Peter
UE73306001	Cooperation agreement regarding the implementation and development of Ex-Vivo Lung Perfusion	Thoraxchirurgie_733	Benazzo Alberto

FA733A0304	A randomized, double-blind, placebo-controlled, parallel group, Phase 3 study, followed by an open-label extension, to evaluate the efficacy of oral belumosudil in adult participants with chronic lung allograft dysfunction (CLAD) following bilateral lung transplantation	Thoraxchirurgie_733	Jaksch Peter
FA670A0108	Erstellen von Kriterien zur Beurteilung der Qualität von Kompositmaterialien und der Langlebigkeit von Kompositfüllungen	Universitätszahnklinik_670	Schedle Andreas
FA670F0205	Characterization of absorbable gradient membrane for periodontal soft tissue augmentation procedures in vitro	Universitätszahnklinik_670	Rausch-Fan Xiaohui
FA670F0502	TMJ SYMPHONY: Systems-integrated model and mechanisms of patient-centered holistic outcomes and network-supported training and therapy	Universitätszahnklinik_670	Sagl Benedikt
FA670F0503	Clinical safety and performance of custom-made zirconia restorations made of Zolid Gen-X and Zolid Bion	Universitätszahnklinik_670	Sagl Benedikt
FW670F0101	Vitamin-D3-Metabolismus in dentalen MSCs	Universitätszahnklinik_670	Andrukhov Oleh
UE67006001	Collaboration Agreement with Amman University - Jordan	Universitätszahnklinik_670	Andrukhov Oleh
UE67006002	Collaboration Agreement with Amman University - Jordan	Universitätszahnklinik_670	Gruber Reinhard
FA743A0106	"Projekttitle (Deutsch): REASSURE - Radium-223 alpha-Strahler in einer Sicherheitsstudie zur Langzeituntersuchung in mCRPC Patienten 1.1. Projekttitle (Englisch): REASSURE - Radium-223 alpha Emitter Agent in Safety Study in mCRPC population for long-term Evaluation"	Urologie_743	Kramer Gero

FA743A0113	A randomized, double-blind, placebo- controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high risk biochemical recurrence (BCR) of prostate cancer	Urologie_743	Kramer Gero
FA743A0114	Prospective, Multi-Country, Observational Study of Clinical Outcomes for Patients With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Treated With ADT plus Apalutamide or Enzalutamide Under Routine Clinical Practice (ArtemisPRO)	Urologie_743	Kramer Gero
FA743A0115	CAAA617D12302: An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617) versus Observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen (PSMA) positive Oligometastatic Prostate Cancer (OMPC)	Urologie_743	Kramer Gero
FA743A0116	A Retrospective, Multicenter Study of Clinical Outcomes in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Patients treated with Apalutamide Under Routine Clinical Practice (ArtemisR)	Urologie_743	Kramer Gero
FA743A0238	A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer(mCRPC)	Urologie_743	Shariat Shahrokh
FA743A0242	Eine Phase-III-Studie zu BCG mit oder ohne Pembrolizumab für Hochrisiko-, nicht-	Urologie_743	Shariat Shahrokh

	muskelinvasiven Blasenkrebs (KEYNOTE-676)		
FA743A0252	A Phase 3b, Randomized, Double-blind Study of Nivolumab Combined with Ipilimumab versus Nivolumab Monotherapy for Patients with Previously Untreated Advanced Renal Cell Carcinoma and Intermediate- or Poor-Risk Factors	Urologie_743	Shariat Shahrokh
FA743A0252	A Phase 3b, Randomized, Double-blind Study of Nivolumab Combined with Ipilimumab versus Nivolumab Monotherapy for Patients with Previously Untreated Advanced Renal Cell Carcinoma and Intermediate- or Poor-Risk Factors	Urologie_743	Shariat Shahrokh
FA743A0254	A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma	Urologie_743	Shariat Shahrokh
FA743A0254	A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma	Urologie_743	Shariat Shahrokh
FA743A0256	A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk	Urologie_743	Shariat Shahrokh

FA743A0256	A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk	Urologie_743	Shariat Shahrokh
FA743A0259	An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy" (MK-6482-011-Site number 1021)	Urologie_743	Shariat Shahrokh
FA743A0261	PSMAfore: A phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of androgen receptor-directed therapy in the Treatment of Taxane Naïve Men with Progressive Metastatic Castrate Resistant Prostate Cancer	Urologie_743	Shariat Shahrokh
FA743A0261	PSMAfore: A phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of androgen receptor-directed therapy in the Treatment of Taxane Naïve Men with Progressive Metastatic Castrate Resistant Prostate Cancer	Urologie_743	Shariat Shahrokh
FA743A0262	PSMAddition: An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone	Urologie_743	Shariat Shahrokh



	Sensitive Prostate Cancer (mHSPC).		
FA743A0262	PSMAddition: An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC).	Urologie_743	Shariat Shahrokh
FA743A0272	HER2 and LA/mUC: A multi-country chart review cohort study	Urologie_743	Shariat Shahrokh
FA743A0273	An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Subjects with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma that Expresses HER2 (IHC 1+ and Greater)	Urologie_743	Shariat Shahrokh
FA743A0274	A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)	Urologie_743	Shariat Shahrokh
FA743A0275	Prediction of neoadjuvant chemotherapy response in patients with MIBC	Urologie_743	Shariat Shahrokh
UE74306002	Vertrag Studienkoordination MUW Novartis	Urologie_743	Kramer Gero
FA690A0402	TBE in Austria - Extended assessment of clinical course including sequelae and vaccination status of virologically	Virologie_307	Aberle Judith

	verified TBE cases based on active surveillance		
FA690A0704	Überwachung der Respiratorischen Rynzytial Viren in Österreich durch das Diagonstische Influenza Netzwerk Österreich	Virologie_307	Redlberger-Fritz Monika

Markus Müller

Rektor